跳至主要内容
临床试验/NCT05918263
NCT05918263招募中不适用

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

Fred Hutchinson Cancer Center4 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2024年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
68
试验地点
4
主要终点
Prostate-Specific Antigen (PSA) Level

研究概览

简要总结

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance.

The name of the study intervention involved in this study is:

Aerobic high-intensity interval training (HIIT) (training exercise intervention)

详细描述

This research study is a randomized controlled study for a home-based, virtually supervised, aerobic exercise intervention for men with prostate cancer at high-risk of progression undergoing active surveillance. There is evidence that exercise may suppress cancer progression, but the evidence is preliminary.

Participants will be randomized into one of two treatment groups: Group A: Aerobic high-intensity interval training (HIIT) versus Group B: Waitlist Control. Randomization means a participant is placed into a study group by chance.

The research study procedures include screening for eligibility, study treatment visits, survey questionnaires, blood tests, and follow-up visits.

Participation in this research study is expected to last about 14 weeks.

It is expected that about 68 people will take part in this research study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Investigator)

盲法说明

Principal investigator blinded to block size

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •Age ≥18 years.
  • •Histologically diagnosed with localized prostate cancer.
  • •Initiating or undergoing active surveillance.
  • •Having a higher risk of progression, defined as meeting one or more of the following: (1) favorable- intermediate risk prostate tumor at diagnosis, (2) obesity (body mass index ≥ 30), and/or (3) self- identified as Black or African American.
  • •No plans for invasive treatment for their prostate cancer in the 12 weeks following the time of enrollment.
  • •Ability to understand and willingness to provide informed consent.

排除标准

  • •Received any invasive curative-intent treatment for prostate cancer, including surgery, chemotherapy, radiation therapy, and hormonal therapy.
  • •Patients with metastasis and/or other active malignancies (except basal cell carcinoma) and/or receiving treatment for those malignancies.
  • •Participating in any (>0 min/week) high-intensity exercise at the time of recruitment.
  • •Having chronic medical conditions that are clinically unstable or uncontrolled with medications, deemed high-risk for exercise. These include but are not limited to unstable cardiac diseases, uncontrolled diabetes, and bone metastases with imminent risk of fracture.
  • •Having a high risk for noncompliance with study procedures. This will be determined by the study team based on the history of missed oncology appointments (i.e., ≥3 no-shows in 6 months) and poor responsiveness during recruitment (i.e., ≥3 unreturned contacts).
  • •Patients who are non-English speaking and unable to complete the participant surveys.

研究组 & 干预措施

Group B: Waitlist Control

Experimental

Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:

  • Testing visits at Week 1 and 14 for physical exams, physical fitness and function assessments, and survey questionnaires.
  • Upon completion of post-intervention assessments, participants will have the option to take part in the 12-week HIIT exercise program.

干预措施: High-Intensity Interval Training Exercise Program (Behavioral)

Group A: HIIT Exercise Program

Experimental

Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:

  • Testing visits at Week 1 and 14 for physical exams, physical fitness and function assessments, survey questionnaires, and cardiopulmonary fitness assessment.
  • Virtual, aerobic training sessions three times weekly with trained oncology exercise specialist.

干预措施: High-Intensity Interval Training Exercise Program (Behavioral)

结局指标

主要结局

Prostate-Specific Antigen (PSA) Level

时间窗: Baseline (Week 1) and post-intervention (Week 14)

The primary outcome is the between-group difference in prostate-specific antigen (PSA) levels post-intervention. Analysis of covariance will be used to detect the difference adjusting for baseline values of the outcome and other covariates.

次要结局

  • Prostate-Specific Antigen (PSA) Velocity(Baseline (Week 1) and post-intervention (Week 14))
  • Prostate-Specific Antigen (PSA) Doubling Time(Baseline (Week 1) and post-intervention (Week 14))
  • Proliferation of LNCaP Prostate Cancer Cell Line(Baseline (Week 1) and post-intervention (Week 14))
  • Muscular Strength(Baseline (Week 1) and post-intervention (Week 14))
  • Short Physical Performance Battery (SPPB)(Baseline (Week 1) and post-intervention (Week 14))
  • Health-Related Quality of Life(Baseline (Week 1) and post-intervention (Week 14))
  • Prostate Cancer-Specific Anxiety(Baseline (Week 1) and post-intervention (Week 14))
  • Fear of Cancer Progression Assessment(Baseline (Week 1) and post-intervention (Week 14))
  • Cardiorespiratory Fitness(Baseline (Week 1) and post-intervention (Week 14))
  • Sleep Quality(Baseline (Week 1) and post-intervention (Week 14))
  • Body Composition(Baseline (Week 1) and post-intervention (Week 14))
  • Prostate Cancer Symptoms(Baseline (Week 1) and post-intervention (Week 14))
  • Exercise Benefits and Barriers(Baseline (Week 1) and post-intervention (Week 14))

研究者

申办方类型
Other
责任方
Sponsor
主要研究者

Christina Dieli-Conwright, PhD

Principal Investigator

Dana-Farber Cancer Institute

研究点 (4)

Loading locations...

相似试验